Cuprina Holdings (Cayman) Ltd - Class A
Research Cuprina Holdings (Cayman) Ltd - Class A (CUPR) on Bullrun: market cap USD 7.83M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCUPR
- ExchangeNASDAQ
- CountrySingapore
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 7.83M
- Financial periodFY2025
- RevenueSGD 38.79K
- Net income-SGD 3.63M
- Free cash flow-SGD 7.15M
- Gross margin-1.3%
Valuation Snapshot
latest market cap is USD 7.83M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SGD 38.79K | -SGD 3.63M | -SGD 7.15M | -1.3% | -17.75 | SGD 2.42M | SGD 128.22K | SGD 3.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 7.83M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.58M | n/a | n/a | n/a |
About Cuprina Holdings (Cayman) Ltd - Class A
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cuprina Holdings (Cayman) Ltd - Class A's market cap?
Cuprina Holdings (Cayman) Ltd - Class A's market capitalization is USD 7.83M.
What does Cuprina Holdings (Cayman) Ltd - Class A do?
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment.